Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported robust fourth-quarter and full-year 2020 results, surpassing net sales and adjusted earnings targets. Q4 net sales rose 38% to $571.2 million, exceeding the 32% CER growth outlook. Adjusted EPS for Q4 increased 42% to $0.68. Full-year net sales grew 23% to $1.87 billion, surpassing the 22% CER outlook, with adjusted EPS rising to $2.15. CEO Thierry Bernard highlighted strong COVID-19 testing demand alongside growth in non-COVID areas, ensuring confidence in 2021 performance amid ongoing strategic initiatives.
QIAGEN has expanded its COVID-19 product lineup by introducing new wastewater testing kits utilizing digital PCR (dPCR) technology. This development aims to enhance global surveillance of COVID-19 by offering precise detection of SARS-CoV-2 in wastewater, which provides crucial epidemiological data. The QIAcuity instruments used for these tests deliver high accuracy, enabling public authorities to monitor community infection dynamics effectively. Dr. Franz Durandet confirmed successful detection of new SARS-CoV-2 variants in trial runs, highlighting the potential of dPCR in environmental biological testing.
QIAGEN N.V. (NYSE: QGEN) has announced the release of its fourth quarter and full-year 2020 results on February 9, 2021, at 22:05 CET / 16:05 EST. A conference call will take place on February 10, at 15:00 CET / 9:00 EST, hosted by CEO Thierry Bernard and CFO Roland Sackers. Interested participants can join the call via phone or access a live webcast. For convenience, it's recommended to join the conference 5-10 minutes early. QGEN's solutions support molecular diagnostics and life sciences, serving over 500,000 customers globally.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) plans to resubmit its QIAreach SARS-CoV-2 Antigen Test to the U.S. FDA for Emergency Use Authorization in Q1 2021 after withdrawing its initial submission in November 2020 due to a chemistry-related issue. The company believes the issue has been resolved and is currently collecting data for resubmission. QIAGEN's CEO, Thierry Bernard, emphasized their commitment to expediting the process to assist in COVID-19 testing. Despite this, the company does not expect any impact on its full-year 2021 sales or adjusted earnings.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) confirmed that its PCR tests for SARS-CoV-2 remain effective against known viral variants. Since May 2020, assessments of the tests against genetic mutations have shown no impact on sensitivity. The company will continue biweekly surveillance of genetic variations. Chief Medical Officer Davide Manissero emphasized the importance of genomic sequencing in monitoring the virus. The report highlights variants like VUI 202012/01, 501Y.V2, and B.1.1.28 P1, which pose increased transmissibility risks.
QIAGEN has appointed Dr. Toralf Haag to its Supervisory Board effective immediately, expanding its membership to seven. Haag, who also joins the Audit Committee, brings extensive experience from his roles in leading companies like Voith and Lonza Group. This strategic move aims to enhance the Board's expertise in Life Sciences and diagnostics. The appointment is part of a broader review process initiated in 2020 aimed at strengthening corporate governance and maximizing stakeholder value.
Summary not available.
QIAGEN N.V. (QGEN) has successfully priced new senior, unsecured convertible bonds totaling $500 million, due in 2027. The bonds, with an initial conversion price set at $80.7218 per share, will be issued at 100% of their principal amount and pay no interest. Concurrently, the company is repurchasing $172.8 million of outstanding convertible notes due in 2021. The proceeds from the new bonds will be used for the repurchase and general corporate purposes. Settlement for both transactions is expected on December 17, 2020.
QIAGEN (NYSE: QGEN) has raised its full-year 2020 forecast for net sales and adjusted earnings per share, anticipating strong performance in 2021 driven by its focus on five growth pillars. The company also plans to expand its Supervisory Board to enhance expertise in Life Sciences and diagnostics. CEO Thierry Bernard acknowledged the team's efforts during the COVID-19 pandemic, highlighting the launch of new testing solutions and increased production capacity. QIAGEN will host a Virtual Deep Dive on December 8 for a strategic and financial update.
QIAGEN N.V. has launched the QuantiFERON SARS-CoV-2 RUO solution, designed to detect T-cell responses to COVID-19. This innovative technology enables researchers to assess immunity levels and disease progression more effectively, as studies show T-cell responses decline slower than antibody responses. With the ability to indicate disease severity and long-term immunity, this tool enhances QIAGEN's COVID-19 portfolio, which includes sample-preparation technology and PCR testing.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
